Imaginostics is a medical imaging diagnostics biotechnology company fulfilling unmet clinical needs in quantitative non-invasive diagnostics. Currently no standardized diagnostic tests exist for small vessel disease, or neurodegenerative diseases, such as dementias like Alzheimer’s disease. Our diagnostic technology, QUTE-CE MRI, fulfills this unmet medical need by providing a new biomarker – which is the measurement of the physiological blood vessel density (or cerebral blood volume CBV). Other techniques in MRI only make relative measurements and and have too high error to be used in common clinical practice. Ultimately, our technology will enable earlier, faster and more quantitative diagnostics insights to help guide care and predict cost for patients.
Clinical Neuroscience Research Partners
Preclinical and Pharmaceutical Neuroscience Research Partners
Craig Ferris PhD
Professor of Psychology and Pharmaceutical Sciences
Director the Center for Translational Neuroimaging (CTNI)